Development of Effective Therapeutics Targeting HER3 for Cancer Treatment
نویسندگان
چکیده
منابع مشابه
Targeting HCV Entry For Development of Therapeutics
Recent progress in defining the molecular mechanisms of Hepatitis C Virus (HCV) entry affords the opportunity to exploit new viral and host targets for therapeutic intervention. Entry inhibitors would limit the expansion of the infected cell reservoir, and would complement the many replication inhibitors now under development. The current model for the pathway of entry involves the initial dock...
متن کاملTargeting Approaches for Effective Therapeutics of Bone Tuberculosis
Bone and Joint Tuberculosis (TB) is the major and commonly occurring type of extra pulmonary mycobacterial disease. Since last twenty years the occurrence of bone TB has augmented marginally in specifically economically backward or developing nations due to malnutrition. Moreover decrease in immunity results in increase in occurrence in patients suffering from AIDS. Bone TB is also found in cas...
متن کاملEmerging therapeutics for targeting Akt in cancer.
The ultimate goal of cancer therapeutic research is to develop effective, targeted therapeutics that exploit the vulnerabilities of cancer cells. The three isoforms of Akt, also known as protein kinase B (PKB), are important mediators of various pathways that transmit mitogenic signals from the cell's exterior to the effector proteins of the cell's interior. Due to Akt\\\\\\\'s importance in ce...
متن کاملTargeting lactate metabolism for cancer therapeutics.
Lactate, once considered a waste product of glycolysis, has emerged as a critical regulator of cancer development, maintenance, and metastasis. Indeed, tumor lactate levels correlate with increased metastasis, tumor recurrence, and poor outcome. Lactate mediates cancer cell intrinsic effects on metabolism and has additional non-tumor cell autonomous effects that drive tumorigenesis. Tumor cells...
متن کاملDevelopment of small molecules targeting the pseudokinase Her3.
Her3 is a member of the human epidermal growth factor receptor (EGFR) tyrosine kinase family, and it is often either overexpressed or deregulated in many types of human cancer. Her3 has not been the subject of small-molecule inhibitor development because it is a pseudokinase and does not possess appreciable kinase activity. We recently reported on the development of the first selective irrevers...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Biological Procedures Online
سال: 2019
ISSN: 1480-9222,1480-9222
DOI: 10.1186/s12575-019-0093-1